{"nctId":"NCT03738865","briefTitle":"G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes","startDateStruct":{"date":"2018-09-27","type":"ACTUAL"},"conditions":["Insulin Hypoglycemia","Type 1 Diabetes Mellitus","Severe Hypoglycemia"],"count":132,"armGroups":[{"label":"G-Pen followed by Novo Glucagon","type":"EXPERIMENTAL","interventionNames":["Drug: G-Pen","Drug: Novo Glucagon"]},{"label":"Novo Glucagon followed by G-Pen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: G-Pen","Drug: Novo Glucagon"]}],"interventions":[{"name":"G-Pen","otherNames":["glucagon"]},{"name":"Novo Glucagon","otherNames":["Glucagen Hypokit"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and non-pregnant females diagnosed with type 1 diabetes (T1D) for at least 24 months.\n2. Current usage of daily insulin treatment that includes having an assigned \"correction factor\" for managing hyperglycemia.\n3. Age 18 to 75 years, inclusive.\n4. Random serum C-peptide concentration \\< 0.6 ng/mL.\n5. Willingness to follow all study procedures, including attending all clinic visits.\n6. Subject has provided informed consent as evidenced by a signed and dated informed consent form (ICF) completed before any trial-related activities occur.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. Glycated hemoglobin (HbA1c) \\> 10% at Screening.\n3. Body mass index (BMI) \\> 40 kg/m2.\n4. Renal insufficiency (serum creatinine greater than 3.0 mg/dL) or end-stage renal disease requiring renal replacement therapy.\n5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal to or greater than 3 times the upper limit of normal.\n6. Hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL.\n7. Hematocrit \\< 30%.\n8. Blood pressure (BP) readings at Screening where systolic blood pressure (SBP) \\< 90 or \\> 150 mm Hg, and diastolic blood pressure (DBP) \\< 50 or \\> 100 mm Hg.\n9. Clinically significant electrocardiogram (ECG) abnormalities.\n10. Use of total insulin dose per day \\> 2 U/kg.\n11. Inadequate venous access.\n12. Congestive heart failure, New York Heart Association (NYHA) class III or IV.\n13. History of myocardial infarction, unstable angina, or revascularization within the past 6 months.\n14. History of a cerebrovascular accident in the past 6 months or with major neurological deficits.\n15. Active malignancy within 5 years from Screening, except basal cell or squamous cell skin cancers. Any history of breast cancer or malignant melanoma will be exclusionary.\n16. Major surgical operation within 30 days prior to Screening.\n17. Current seizure disorder (other than with suspect or documented hypoglycemia).\n18. Current bleeding disorder, treatment with warfarin, or platelet count below 50 Ã— 109 per liter.\n19. History of pheochromocytoma or disorder with increased risk of pheochromocytoma (multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis, or Von Hippel-Lindau disease).\n20. History of insulinoma.\n21. History of allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products or to any of the excipients (DMSO and trehalose) in the investigational formulation.\n22. History of glycogen storage disease.\n23. Subject tests positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection (hepatitis B surface antigen positive \\[HBsAg+\\]) at Screening.\n24. Active substance other than tetrahydrocannabinol (THC) or alcohol abuse (more than 21 drinks per week for male subjects or 14 drinks per week for female subject).\n25. Administration of glucagon within 7 days of Screening.\n26. Participation in other studies involving administration of an investigational drug or device within 30 days or 5 half-lives, whichever is longer, before Screening for the current study and during participation in the current study.\n27. Any other reason the Investigator deems exclusionary.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Severe Hypoglycemia Rescue","description":"Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) or an increase in plasma glucose concentration \\> 20 mg/dL (\\> 1.11 mmol/L) within 30 minutes after administration of glucagon","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Glucose Response 1","description":"Number of subjects with an increase in plasma glucose concentration from below 54 mg/dL (3 mmol/L) to greater than 70 mg/dL (3.89 mmol/L) within 30 minutes of a decision to dose","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Glucose Response 2","description":"Number of subjects with an increase in plasma glucose concentration \\> 20 mg/dL (\\> 1.11 mmol/L) after administration of glucagon.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]},{"type":"SECONDARY","title":"Administration Time","description":"Mean time (minutes) to administer study drug from a decision to dose","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"0.530"},{"groupId":"OG001","value":"1.76","spread":"0.678"}]}]}]},{"type":"SECONDARY","title":"Hypoglycemia Resolution","description":"Mean time (minutes) to complete resolution of the overall sensation of hypoglycemia from a decision to dose","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.69","spread":"7.428"},{"groupId":"OG001","value":"15.32","spread":"8.479"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":127},"commonTop":["Nausea","Vomiting","Headache"]}}}